The tyrosine kinase inhibitor nilotinib selectively inhibits cyp2c8 activities in human liver microsomes

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 6, 2013, Pages 462-467

  Kim, Min Jung ^a   Lee, Jae Won ^b   Oh, Kyung Suk ^a   Choi, Chang Soo ^c   Kim, Kwang Hee ^c   Han, Won Seok ^d   Yoon, Chang No ^d   Chung, Eun Sook ^a   Kim, Dong Hyun ^a   Shin, Jae Gook ^a  

^a Inje University College of Medicine   (South Korea)

^b Department of Business Development   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

Author keywords

CYP2C8; Docking simulation; Microsomes; Nilotinib; Paclitaxel; Selective inhibition

Indexed keywords

AMODIAQUINE; CYTOCHROME P450 2C8; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; MIDAZOLAM; NILOTINIB; PACLITAXEL; RECOMBINANT ENZYME; ROSIGLITAZONE; SUNITINIB;

ARTICLE; BACULOVIRUS; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DEMETHYLATION; DRUG BINDING; DRUG HYDROXYLATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSECT; LIVER MICROSOME; MOLECULAR DOCKING; PROTEIN EXPRESSION;

ARYL HYDROCARBON HYDROXYLASES; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84892992744     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-019     Document Type: Article

References (21)

1. Deremer, D. L., Ustun, C. and Natarajan, K.: Nilotinib: a secondgeneration tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin. Ther., 30: 1956-1975 (2008)
2. Golemovic, M., Verstovsek, S., Giles, F., Cortes, J., Manshouri, T., Manley, P. W., Mestan, J., Dugan, M., Alland, L., Griffin, J. D., Arlinghaus, R. B., Sun, T., Kantarjian, H. and Beran, M.: AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res., 11: 4941-4947
3. Verstovsek, S., Golemovic, M., Kantarjian, H., Manshouri, T., Estrov, Z., Manley, P., Sun, T., Arlinghaus, R. B., Alland, L., Dugan, M., Cortes, J., Giles, F. and Beran, M.: AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphiapositive acute lymphoblastic leukemia cells. Cancer, 104: 1230-1236 (2005).
4. Weisberg, E., Manley, P. W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R. D., Gilliland, D. G. and Griffin, J. D.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7: 129-141 (2005)
5. Haouala, A., Widmer, N., Duchosal, M. A., Montemurro, M., Buclin, T. and Decosterd, L. A.: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood, 117: e75-e87 (2011)
6. Tanaka, C., Yin, O. Q., Sethuraman, V., Smith, T., Wang, X., Grouss, K., Kantarjian, H., Giles, F., Ottmann, O. G., Galitz, L. and Schran, H.: Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin. Pharmacol. Ther., 87: 197-203 (2010)
7. Tanaka, C., Yin, O. Q., Smith, T., Sethuraman, V., Grouss, K., Galitz, L., Harrell, R. and Schran, H.: Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J. Clin. Pharmacol., 51: 75-83 (2011)
8. Yin, O. Q., Gallagher, N., Li, A., Zhou, W., Harrell, R. and Schran, H.: Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J. Clin. Pharmacol., 50: 188-194 (2010)
9. Tasigna (nilotinib) [package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October (2011). http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/022068s007lbl.pdf
10. Yin, O. Q., Gallagher, N., Fischer, D., Zhao, L., Zhou, W., Leroy, E., Golor, G. and Schran, H.: Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin. Drug Investig., 31: 169-179 (2011)
11. Shin, J. G., Soukhova, N. and Flockhart, D. A.: Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro:preferential inhibition of CYP2D6. Drug Metab. Dispos., 27: 1078-1084(1999)
12. Kim, M. J., Kim, H., Cha, I. J., Park, J. S., Shon, J. H., Liu, K. H. and Shin, J. G.: High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom., 19: 2651-2658 (2005)
13. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994)
14. Lai, X. S., Yang, L. P., Li, X. T., Liu, J. P., Zhou, Z. W. and Zhou, S. F.: Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr. Drug Metab., 10: 1009-1047 (2009)
15. Liu, Y., Ramirez, J. and Ratain, M. J.: Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br. J. Clin. Pharmacol., 71: 917-920 (2011).
16. Walsky, R. L., Obach, R. S., Gaman, E. A., Gleeson, J. P. and Proctor, W. R.: Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab. Dispos., 33: 413-418 (2005).
17. Guengerich, F. P., Muller-Enoch, D. and Blair, I. A.: Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol., 30: 287- 295 (1986).
18. Otton, S. V., Brinn, R. U. and Gram, L. F.: In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab. Dispos., 16: 15-17 (1988)
19. McLaughlin, L. A., Paine, M. J., Kemp, C. A., Marechal, J. D., Flanagan, J. U., Ward, C. J., Sutcliffe, M. J., Roberts, G. C. and Wolf, C. R.: Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key activesite residues in quinidine binding. J. Biol. Chem., 280: 38617-38624 (2005)
20. van Erp, N. P., Gelderblom, H. and Guchelaar, H. J.: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat. Rev., 35: 692-706 (2009)
21. Trent, J. and Molimard, M.: Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. Semin. Oncol., 38 Suppl 1: S28-S33 (2011)